Treatment of cutaneous melanoma: current approaches and future prospects

References

• JemalASiegelRWardECancer Statistics, 2008CA Cancer J Clin2008582719618287387
   PubMed Web of Science ®Google Scholar
• LinosESwetterSMCockburnmgColditzGAClarkeCAIncreasing burden of melanoma in the United StatesJ Invest Dermatol200912971666167419131946
   PubMed Web of Science ®Google Scholar
• McGovernVJCochranAJVan der EschEPLittleJHMacLennanRThe classification of malignant melanoma, its histological reporting and registration: a revision of the 1972 Sydney classificationPathology198618112213725419
   PubMed Web of Science ®Google Scholar
• CurtinJAFridlyandJKageshitaTDistinct sets of genetic alterations in melanomaN Engl J Med2005353202135214716291983
   PubMed Web of Science ®Google Scholar
• VeronesiUCascinelliNAdamusJThin stage I primary cutaneous malignant melanoma. Comparison of excision with margins of 1 or 3 cmN Engl J Med198831818115911623079582
   PubMed Web of Science ®Google Scholar
• VeronesiUCascinelliNNarrow excision (1-cm margin). A safe procedure for thin cutaneous melanomaArch Surg199112644384412009058
   PubMedGoogle Scholar
• Cohn-CedermarkGRutqvistLEAnderssonRLong term results of a randomized study by the Swedish Melanoma Study Group on 2-cm versus 5-cm resection margins for patients with cutaneous melanoma with a tumor thickness of 0.8–2.0 mmCancer20008971495150111013363
   PubMed Web of Science ®Google Scholar
• KhayatDRixeOMartinGSurgical margins in cutaneous melanoma (2 cm versus 5 cm for lesions measuring less than 2.1-mm thick)Cancer20039781941194612673721
   PubMed Web of Science ®Google Scholar
• ThomasJMNewton-BishopJA’HernRExcision margins in high-risk malignant melanomaN Engl J Med2004350875776614973217
   PubMed Web of Science ®Google Scholar
• HeatonKMSussmanJJGershenwaldJESurgical margins and prognostic factors in patients with thick (>4 mm) primary melanomaAnn Surg Oncol1998543223289641453
   PubMed Web of Science ®Google Scholar
• CoitDGAndtbackaRBichakjianCKMelanomaJ Natl Compr Canc Netw20097325027519401060
   PubMed Web of Science ®Google Scholar
• BalchCMGershenwaldJESoongSFinal Version of 2009 AJCC Melanoma Staging and ClassificationJ Clin Oncol2009 Available at: http://www.ncbi.nlm.nih.gov/pubmed/19917835 [Accessed Nov 23, 2009].
   Google Scholar
• KirkwoodJMManolaJIbrahimJA pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanomaClin Cancer Res20041051670167715014018
   PubMed Web of Science ®Google Scholar
• EggermontASuciuSTestoriAPatelPSpatzAUlceration of primary melanoma and responsiveness to adjuvant interferon therapy: Analysis of the adjuvant trials EORTC18952 and EORTC18991 in 2,644 patientsJ Clin Oncol20092715s Suppl; abstr 9007.
   Google Scholar
• LensMBDawesMNewton-BishopJAGoodacreTTumour thickness as a predictor of occult lymph node metastases in patients with stage I and II melanoma undergoing sentinel lymph node biopsyBr J Surg200289101223122712296887
   PubMed Web of Science ®Google Scholar
• WarychaMAZakrzewskiJNiQMeta-analysis of sentinel lymph node positivity in thin melanoma (≤1 mm)Cancer2009115486987919117354
   PubMed Web of Science ®Google Scholar
• McMastersKMWongSLEdwardsMJFactors that predict the presence of sentinel lymph node metastasis in patients with melanomaSurgery2001130215115611490343
   PubMed Web of Science ®Google Scholar
• MortonDLWenDRWongJHTechnical details of intraoperative lymphatic mapping for early stage melanomaArch Surg199212743923991558490
   PubMed Web of Science ®Google Scholar
• ReintgenDCruseCWWellsKThe orderly progression of melanoma nodal metastasesAnn Surg199422067597677986143
   PubMed Web of Science ®Google Scholar
• WrightsonWRWongSLEdwardsMJComplications associated with sentinel lymph node biopsy for melanomaAnn Surg Oncol200310667668012839853
   PubMed Web of Science ®Google Scholar
• MortonDLThompsonJFCochranAJSentinel-Node Biopsy or Nodal Observation in MelanomaN Engl J Med2006355131307131717005948
   PubMed Web of Science ®Google Scholar
• van AkkooiARutkowskiPvan der PloegILong-term follow-up of patients with minimal sentinel node tumor burden (< 0.1 mm) according to Rotterdam criteria: A study of the EORTC Melanoma GroupJ Clin Oncol20092715s Suppl; abstr 9005.
   Google Scholar
• VeronesiUAdamusJBandieraDCDelayed regional lymph node dissection in stage I melanoma of the skin of the lower extremitiesCancer19824911242024307074555
   PubMed Web of Science ®Google Scholar
• SimFHTaylorWFPritchardDJSouleEHLymphadenectomy in the management of stage I malignant melanoma: a prospective randomized studyMayo Clin Proc19866196977053747613
   PubMed Web of Science ®Google Scholar
• BalchCMSoongSJBartolucciAAEfficacy of an elective regional lymph node dissection of 1 to 4 mm thick melanomas for patients 60 years of age and youngerAnn Surg19962243255263 discussion 263–266.8813254
   PubMed Web of Science ®Google Scholar
• BalchCMSoongSRossMILong-term results of a multi-institutional randomized trial comparing prognostic factors and surgical results for intermediate thickness melanomas (1.0 to 4.0 mm). Intergroup Melanoma Surgical TrialAnn Surg Oncol200072879710761786
   PubMed Web of Science ®Google Scholar
• CascinelliNMorabitoASantinamiMMacKieRMBelliFImmediate or delayed dissection of regional nodes in patients with melanoma of the trunk: a randomised trial. WHO Melanoma ProgrammeLancet199835191057937969519951
   PubMed Web of Science ®Google Scholar
• AloiaTAGershenwaldJEAndtbackaRHUtility of computed tomography and magnetic resonance imaging staging before completion lymphadenectomy in patients with sentinel lymph node-positive melanomaJ Clin Oncol200624182858286516782925
   PubMed Web of Science ®Google Scholar
• GoldJSJaquesDPBusamKJBradyMSCoitDGYield and predictors of radiologic studies for identifying distant metastases in melanoma patients with a positive sentinel lymph node biopsyAnn Surg Oncol20071472133214017453294
   PubMed Web of Science ®Google Scholar
• MirandaEPGertnerMWallJRoutine imaging of asymptomatic melanoma patients with metastasis to sentinel lymph nodes rarely identifies systemic diseaseArch Surg20041398831836 discussion 836–837.15302691
   PubMedGoogle Scholar
• NCCN Melanoma Guidelines Available at: http://www.nccn.org/professionals/physician_gls/PDF/melanoma.pdf [Accessed Nov 30, 2009].
   Google Scholar
• BuzaidACTinocoLRossMILeghaSSBenjaminRSRole of computed tomography in the staging of patients with local-regional metastases of melanomaJ Clin Oncol1995138210421087636554
   PubMed Web of Science ®Google Scholar
• JohnsonTMFaderDJChangAEComputed tomography in staging of patients with melanoma metastatic to the regional nodesAnn Surg Oncol1997453964029259966
   PubMed Web of Science ®Google Scholar
• KuvshinoffBWKurtzCCoitDGComputed tomography in evaluation of patients with stage III melanomaAnn Surg Oncol1997432522589142387
   PubMed Web of Science ®Google Scholar
• WangTSJohnsonTMCascadePNEvaluation of staging chest radiographs and serum lactate dehydrogenase for localized melanomaJ Am Acad Dermatol200451339940515337983
   PubMed Web of Science ®Google Scholar
• YancovitzMFineltNWarychaMARole of radiologic imaging at the time of initial diagnosis of stage T1b–T3b melanomaCancer200711051107111417620286
   PubMed Web of Science ®Google Scholar
• HendersonMBurmeisterBThompsonJAdjuvant radiotherapy and regional lymph node field control in melanoma patients after lymphadenectomy: Results of an intergroup randomized trial (ANZMTG 01.02/TROG 02.01)J Clin Oncol (Meeting Abstracts)20092718s Suppl; abstr LBA9084.
   Google Scholar
• KirkwoodJMIbrahimJGSondakVKHigh- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J Clin Oncol200018122444245810856105
   PubMed Web of Science ®Google Scholar
• EggermontAMMSuciuSMacKieRPost-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trialLancet200536694921189119616198768
   PubMed Web of Science ®Google Scholar
• PehambergerHSoyerHPSteinerAAdjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative GroupJ Clin Oncol1998164142514299552047
   PubMed Web of Science ®Google Scholar
• GrobJJDrenoBde la SalmonièrePRandomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on MelanomaLancet19983519120190519109654256
   PubMed Web of Science ®Google Scholar
• KirkwoodJMIbrahimJGSondakVKHigh- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190J Clin Oncol200018122444245810856105
   PubMed Web of Science ®Google Scholar
• PectasidesDDafniUBafaloukosDRandomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanomaJ Clin Oncol200927693994419139440
   PubMed Web of Science ®Google Scholar
• Phase III randomized adjuvant study of high-dose interferon alfa-2b therapy in patients with stage II or III melanoma Available at: http://www.cancer.gov/clinicaltrials/ECOG-1697 [Accessed Dec 1, 2009].
   Google Scholar
• EggermontAMMSuciuSSantinamiMAdjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trialLancet2008372963311712618620949
   PubMed Web of Science ®Google Scholar
• YoungJWSzabolcsPMooreMAIdentification of dendritic cell colony-forming units among normal human CD34+ bone marrow progenitors that are expanded by c-kit-ligand and yield pure dendritic cell colonies in the presence of granulocyte/macrophage colony-stimulating factor and tumor necrosis factor alphaJ Exp Med19951824111111197561684
   PubMed Web of Science ®Google Scholar
• SzabolcsPMooreMAYoungJWExpansion of immunostimulatory dendritic cells among the myeloid progeny of human CD34+ bone marrow precursors cultured with c-kit ligand, granulocyte-macrophage colony-stimulating factor, and TNF-alphaJ Immunol199515411585158617538534
   PubMed Web of Science ®Google Scholar
• GrabsteinKHUrdalDLTushinskiRJInduction of macrophage tumoricidal activity by granulocyte-macrophage colony-stimulating factorScience198623247495065083083507
   PubMed Web of Science ®Google Scholar
• ThomassenMJBarnaBPRankinDWiedemannHPAhmadMDifferential effect of recombinant granulocyte macrophage colony-stimulating factor on human monocytes and alveolar macrophagesCancer Res19894915408640892545332
   PubMed Web of Science ®Google Scholar
• SpitlerLEWeberRWAllenRERecombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF, sargramostim) administered for 3 years as adjuvant therapy of stages II(T4), III, and IV melanomaJ Immunother200932663263719483646
   PubMed Web of Science ®Google Scholar
• DaudAIMirzaNLenoxBPhenotypic and functional analysis of dendritic cells and clinical outcome in patients with high-risk melanoma treated with adjuvant granulocyte macrophage colony-stimulating factorJ Clin Oncol200826193235324118591558
   PubMed Web of Science ®Google Scholar
• LawsonDLeeSKirkwoodJE4697. Randomized, placebo-controlled phase III trial of yeast derived GM-CSF vs peptide vaccination vs GM-CSF + peptide vaccination vs placebo in patients with no evidence of disease after resection of locally advanced and/or stage IV melanoma. Data Analysis as of Sep 15, 2009Baltimore, MDEastern Cooperative Oncology Group Meeting2009
   Google Scholar
• LawsonDECOG trial E4697 preliminary results, personal communication
   Google Scholar
• HerseyPCoatesASMcCarthyWHAdjuvant immunotherapy of patients with high-risk melanoma using vaccinia viral lysates of melanoma: results of a randomized trialJ Clin Oncol200220204181419012377961
   PubMed Web of Science ®Google Scholar
• SondakVMelanoma vaccines: what have we learned? Available at: http://www.societymelanomaresearch.org/pdf/melanoma_vaccines.pdf [Accessed Dec 8, 2009].
   Google Scholar
• SondakVKLiuPTuthillRJAdjuvant immunotherapy of resected, intermediate-thickness, node-negative melanoma with an allogeneic tumor vaccine: overall results of a randomized trial of the Southwest Oncology GroupJ Clin Oncol20022082058206611956266
   PubMed Web of Science ®Google Scholar
• EggermontASuciuSRukaWEORTC 18961: Post-operative adjuvant ganglioside GM2-KLH21 vaccination treatment vs observation in stage II (T3-T4N0M0) melanoma: 2nd interim analysis led to an early disclosure of the resultsJ Clin Oncol (Meeting Abstracts)200826520 Suppl abstr 9004.
   Google Scholar
• WeberJOvercoming immunologic tolerance to melanoma: targeting CTLA-4 with ipilimumab (MDX-010)Oncologist200813Suppl 4162519001147
   PubMed Web of Science ®Google Scholar
• WeberJSarnaikATarganSPhase II trial of extended dose anti-CTLA-4 antibody ipilimumab (formerly MDX-010) with a multipeptide vaccine for resected stages IIIC and IV melanomaJ Clin Oncol (Meeting Abstracts)20092715s Suppl; abstr 9023.
   Google Scholar
• ClinicalTrials.govEfficacy study of ipilimumab versus placebo to prevent recurrence after complete resection of high risk stage III melanoma Available at: http://clinicaltrials.gov/ct2/show/NCT00636168. Accessed Dec 14, 2009.
   Google Scholar
• KimKBLeghaSSGonzalezRA randomized phase III trial of biochemotherapy versus interferon-alpha-2b for adjuvant therapy in patients at high risk for melanoma recurrenceMelanoma Res2009191424919430405
   PubMed Web of Science ®Google Scholar
• RadnyPCaroliUMBauerJPhase II trial of intralesional therapy with interleukin-2 in soft-tissue melanoma metastasesBr J Cancer20038991620162614583759
   PubMed Web of Science ®Google Scholar
• GreenDSBodman-SmithMDDalgleishAGFischerMDPhase I/II study of topical imiquimod and intralesional interleukin-2 in the treatment of accessible metastases in malignant melanomaBr J Dermatol2007156233734517223875
   PubMed Web of Science ®Google Scholar
• DaudAIDeContiRCAndrewsSPhase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanomaJ Clin Oncol200826365896590319029422
   PubMed Web of Science ®Google Scholar
• FrakerDLManagement of in-transit melanoma of the extremity with isolated limb perfusionCurr Treat Options Oncol20045317318415115646
   PubMedGoogle Scholar
• AlexanderHRFrakerDLBartlettDLAnalysis of factors influencing outcome in patients with in-transit malignant melanoma undergoing isolated limb perfusion using modern treatment parametersJ Clin Oncol201028111411819901107
   PubMed Web of Science ®Google Scholar
• KlaaseJMKroonBBvan GeelANPrognostic factors for tumor response and limb recurrence-free interval in patients with advanced melanoma of the limbs treated with regional isolated perfusion with melphalanSurgery1994115139458284759
   PubMed Web of Science ®Google Scholar
• CornettWRMcCallLMPetersenRPRandomized multicenter trial of hyperthermic isolated limb perfusion with melphalan alone compared with melphalan plus tumor necrosis factor: American College of Surgeons Oncology Group Trial Z0020J Clin Oncol200624254196420116943537
   PubMed Web of Science ®Google Scholar
• VrouenraetsBCKlaaseJMKroonBBLong-term morbidity after regional isolated perfusion with melphalan for melanoma of the limbs. The influence of acute regional toxic reactionsArch Surg1995130143477802575
   PubMedGoogle Scholar
• OvergaardJGonzalez GonzalezDHulshofMCRandomised trial of hyperthermia as adjuvant to radiotherapy for recurrent or metastatic malignant melanoma. European Society for Hyperthermic OncologyLancet199534589495405437776772
   PubMed Web of Science ®Google Scholar
• OvergaardJGonzalez GonzalezDHulshofMCHyperthermia as an adjuvant to radiation therapy of recurrent or metastatic malignant melanoma. A multicentre randomized trial by the European Society for Hyperthermic OncologyInt J Hyperthermia19961213208676005
   PubMed Web of Science ®Google Scholar
• KornELLiuPLeeSJMeta-analysis of phase II cooperative group trials in metastatic stage IV melanoma to determine progression-free and overall survival benchmarks for future phase II trialsJ Clin Oncol200826452753418235113
   PubMed Web of Science ®Google Scholar
• HermanPMachadoMACMontagniniALSelected patients with metastatic melanoma may benefit from liver resectionWorld J Surg200731117117417171491
   PubMed Web of Science ®Google Scholar
• RoseDMEssnerRHughesTMSurgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experienceArch Surg2001136895095511485537
   PubMedGoogle Scholar
• Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. The International Registry of Lung MetastasesJ Thorac Cardiovasc Surg1997113137499011700
   PubMed Web of Science ®Google Scholar
• AtkinsMBLotzeMTDutcherJPHigh-dose recombinant interleukin-2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993J Clin Oncol19991772105211610561265
   PubMed Web of Science ®Google Scholar
• AtkinsMBKunkelLSznolMRosenbergSAHigh-dose recombinant interleukin-2 therapy in patients with metastatic melanoma: long-term survival updateCancer J Sci Am20006Suppl 1S11S1410685652
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangJCWhiteDESteinbergSMDurability of complete responses in patients with metastatic cancer treated with high-dose interleukin-2: identification of the antigens mediating responseAnn Surg199822833073199742914
   PubMed Web of Science ®Google Scholar
• RosenbergSAYangJCTopalianSLTreatment of 283 consecutive patients with metastatic melanoma or renal cell cancer using high-dose bolus interleukin-2JAMA1994271129079138120958
   PubMed Web of Science ®Google Scholar
• RoyalRESteinbergSMKrouseRSCorrelates of response to interleukin-2 therapy in patients treated for metastatic renal cancer and melanomaCancer J Sci Am19962291989166506
   PubMedGoogle Scholar
• SchwartzentruberDLawsonDRichardsJA phase III multi-institutional randomized study of immunization with the gp-100:209–217(210M) peptide followed by high-dose interleukin-2 compared with high-dose interleukin-2 alone in patients with metastatic melanomaJ Clin Oncol (Meeting Abstracts)20092718s Suppl; abstr CRA9011.
   Google Scholar
• SosmanJACarrilloCUrbaWJThree phase II cytokine working group trials of gp-100 (210M) peptide plus high-dose interleukin-2 in patients with HLA-A2-positive advanced melanomaJ Clin Oncol200826142292229818467720
   PubMed Web of Science ®Google Scholar
• LeachDRKrummelMFAllisonJPEnhancement of antitumor immunity by CTLA-4 blockadeScience19962715256173417368596936
   PubMed Web of Science ®Google Scholar
• HamidOChinKLiJDose effect of ipilimumab in patients with advanced melanoma: Results from a phase II, randomized, dose-ranging studyJ Clin Oncol (Meeting Abstracts)200826520 Suppl abstr 9025.
   Google Scholar
• O’DaySIbrahimRDePrilVEfficacy and safety of ipilimumab induction and maintenance dosing in patients with advanced melanoma who progressed on one or more prior therapiesJ Clin Oncol (Meeting Abstracts)200826520 Suppl abstr 9021.
   Google Scholar
• O’DaySWeberJLebbeCEffect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trialsJ Clin Oncol (Meeting Abstracts)20092715s Suppl; abstr 9033.
   Google Scholar
• AttiaPPhanGQMakerAVAutoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4J Clin Oncol200523256043605316087944
   PubMed Web of Science ®Google Scholar
• SandersonKScotlandRLeePAutoimmunity in a phase I trial of a fully human anti-cytotoxic T-lymphocyte antigen-4 monoclonal antibody with multiple melanoma peptides and Montanide ISA 51 for patients with resected stages III and IV melanomaJ Clin Oncol200523474175015613700
   PubMed Web of Science ®Google Scholar
• HodiFHoosAIbrahimRNovel efficacy criteria for antitumor activity to immunotherapy using the example of ipilimumab, an anti-CTLA-4 monoclonal antibodyJ Clin Oncol (Meeting Abstracts)200826Suppl abstr 3008.
   Google Scholar
• WolchokJIbrahimRDePrilVAntitumor response and new lesions in advanced melanoma patients on ipilimumab treatmentJ Clin Oncol (Meeting Abstracts)200826520 Suppl May 20 Suppl; abstr 3020.
   Google Scholar
• DowneySGKlapperJASmithFOPrognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockadeClin Cancer Res20071322 Pt 16681668817982122
   PubMed Web of Science ®Google Scholar
• HodiFSO’DaySJMcDermottDFImproved survival with ipilimumab in patients with metastatic melanomaN Engl J Med2010614 [Epub ahead of print].
   Web of Science ®Google Scholar
• FischkoffSHershEWeberJDurable responses and long-term progression-free survival observed in a phase II study of MDX-010 alone or in combination with dacarbazine (DTIC) in metastatic melanomaJ Clin Oncol (Meeting Abstracts)20052316s, part I of II (Jun 1 Supplement)):abstr 7525.
   Google Scholar
• HershEWeberJPowderlyJDisease control and long-term survival in chemotherapy-naive patients with advanced melanoma treated with ipilimumab (MDX-010) with or without dacarbazineJ Clin Oncol (Meeting Abstracts)200826520 Suppl abstr 9022.
   Google Scholar
• ClinicalTrials.govDacarbazine and ipilimumab vs dacarbazine with placebo in untreated unresectable stage III or IV melanoma Available at: http://clinicaltrials.gov/ct2/show/NCT00324155. Accessed Dec 13, 2009.
   Google Scholar
• MakerAVPhanGQAttiaPTumor regression and autoimmunity in patients treated with cytotoxic T lymphocyte-associated antigen 4 blockade and interleukin-2: a phase I/II studyAnn Surg Oncol200512121005101616283570
   PubMed Web of Science ®Google Scholar
• RosenbergSAPackardBSAebersoldPMUse of tumor-infiltrating lymphocytes and interleukin-2 in the immunotherapy of patients with metastatic melanoma. A preliminary reportN Engl J Med198831925167616803264384
   PubMed Web of Science ®Google Scholar
• RosenbergSAYannelliJRYangJCTreatment of patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and interleukin-2J Natl Cancer Inst19948615115911668028037
   PubMed Web of Science ®Google Scholar
• RosenbergSARestifoNPYangJCMorganRADudleyMEAdoptive cell transfer: a clinical path to effective cancer immunotherapyNat Rev Cancer20088429930818354418
   PubMed Web of Science ®Google Scholar
• Clinical TrialsDudleyMEYangJCSherryRAdoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimensJ Clin Oncol200826325233523918809613
   PubMed Web of Science ®Google Scholar
• StratenPTBeckerJCAdoptive cell transfer in the treatment of metastatic melanomaJ Invest Dermatol 0;129122743274519901944
   PubMed Web of Science ®Google Scholar
• Clinical TrialsLymphodepletion plus adoptive cell transfer with or without dendritic cell immunization Available at: http://clinicaltrials.gov/ct2/show/NCT00338377?term=adoptive+cell+transfer+AND+melanoma&rank=1. Accessed Dec 14, 2009.
   Google Scholar
• Clinical TrialsLymphodepletion plus adoptive cell transfer with high dose interleukin-2 in patients with metastatic melanoma Available at: http://clinicaltrials.gov/ct2/show/NCT01005745?term=adoptive+cell+transfer+AND+melanoma&rank=2. Accessed Dec 14, 2009.
   Google Scholar
• Clinical TrialsStudy of gene modified immune cells in patients with advanced melanoma Available at: http://clinicaltrials.gov/ct2/show/NCT00910650?term=adoptive+cell+transfer+AND+melanoma&rank=6. Accessed Dec 14, 2009.
   Google Scholar
• LuikartSDKennealeyGTKirkwoodJMRandomized phase III trial of vinblastine, bleomycin, and cis-dichlorodiammine-platinum versus dacarbazine in malignant melanomaJ Clin Oncol1984231641686199481
   PubMed Web of Science ®Google Scholar
• ChapmanPBEinhornLHMeyersMLPhase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanomaJ Clin Oncol19991792745275110561349
   PubMed Web of Science ®Google Scholar
• MiddletonMRGrobJJAaronsonNRandomized phase III study of temozolomide versus dacarbazine in the treatment of patients with advanced metastatic malignant melanomaJ Clin Oncol200018115816610623706
   PubMed Web of Science ®Google Scholar
• SchadendorfDUgurelSSchuler-ThurnerBDacarbazine (DTIC) versus vaccination with autologous peptide-pulsed dendritic cells (DC) in first-line treatment of patients with metastatic melanoma: a randomized phase III trial of the DC study group of the DeCOGAnn Oncol200617456357016418308
   PubMed Web of Science ®Google Scholar
• AtkinsMSosmanJCytotoxic chemotherapy and biochemotherapy for metastatic melanoma Available at: http://www.uptodate.com/online/content/topic.do?topicKey=skin_can/4732&selectedTitle=1%7E150&source=search_result [Accessed Dec 14, 2009].
   Google Scholar
• HillGJKrementzETHillHZDimethyl triazeno imidazole carboxamide and combination therapy for melanoma. IV. Late results after complete response to chemotherapy (Central Oncology Group protocols 7130, 7131, and 7131A)Cancer1984536129913056362841
   PubMed Web of Science ®Google Scholar
• EtonOLeghaSSBedikianAYSequential biochemotherapy versus chemotherapy for metastatic melanoma: results from a phase III randomized trialJ Clin Oncol20022082045205211956264
   PubMed Web of Science ®Google Scholar
• LeghaSSRingSPapadopoulosNA prospective evaluation of a triple-drug regimen containing cisplatin, vinblastine, and dacarbazine (CVD) for metastatic melanomaCancer19896410202420292804890
   PubMed Web of Science ®Google Scholar
• PaulMJSummersYCalvertAHEffect of temozolomide on central nervous system relapse in patients with advanced melanomaMelanoma Res200212217517811930115
   PubMed Web of Science ®Google Scholar
• EinzigAIHochsterHWiernikPHA phase II study of taxol in patients with malignant melanomaInvest New Drugs19919159641673965
   PubMed Web of Science ®Google Scholar
• BedikianAYWeissGRLeghaSSPhase II trial of docetaxel in patients with advanced cutaneous malignant melanoma previously untreated with chemotherapyJ Clin Oncol19951312289528998523052
   PubMed Web of Science ®Google Scholar
• AamdalSWolffIKaplanSDocetaxel (Taxotere) in advanced malignant melanoma: a phase II study of the EORTC Early Clinical Trials GroupEur J Cancer199430A8106110647654429
   PubMed Web of Science ®Google Scholar
• HauschildAAgarwalaSSTrefzerUResults of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanomaJ Clin Oncol200927172823283019349552
   PubMed Web of Science ®Google Scholar
• GlantzMJChoyHKearnsCMPaclitaxel disposition in plasma and central nervous systems of humans and rats with brain tumorsJ Natl Cancer Inst19958714107710817616600
   PubMedGoogle Scholar
• FojoTMenefeeMMechanisms of multidrug resistance: the potential role of microtubule-stabilizing agentsAnn Oncol200718Suppl 5v3v817656560
   PubMed Web of Science ®Google Scholar
• KlarUBuchmannBSchwedeWTotal synthesis and antitumor activity of ZK-EPO: the first fully synthetic epothilone in clinical developmentAngew Chem Int Ed Engl200645477942794817006870
   PubMed Web of Science ®Google Scholar
• HoffmannJVitaleIBuchmannBImproved cellular pharmacokinetics and pharmacodynamics underlie the wide anticancer activity of sagopiloneCancer Res200868135301530818593931
   PubMed Web of Science ®Google Scholar
• HoffmannJFichtnerILemmMSagopilone crosses the blood-brain barrier in vivo to inhibit brain tumor growth and metastasesNeuro-oncology200911215816618780814
   PubMed Web of Science ®Google Scholar
• SilvaniAGavianiPFiumaniASystemic sagopilone (ZK-EPO) treatment of patients with recurrent malignant gliomasJ Neurooncol2009 Available at: http://www.ncbi.nlm.nih.gov/pubmed/19381446 [Accessed Jul 22, 2009].
   Google Scholar
• StuppRTosoniATaalWA phase II multicenter trial of sagopilone in patients with recurrent glioblastomaJournal of Clinical Oncology200826 Abstract 2015.
   Web of Science ®Google Scholar
• ASCOPhase II trial of sagopilone (ZK-EPO), a novel synthetic epothilone, with significant activity in metastatic melanoma Available at: http://www.asco.org/ASCOv2/Meetings/Abstracts?&vmview=abst_detail_view&confID=65&abstractID=30552. Accessed Jul 22, 2009.
   Google Scholar
• BajettaEDel VecchioMNovaPMulticenter phase III randomized trial of polychemotherapy (CVD regimen) versus the same chemotherapy (CT) plus subcutaneous interleukin-2 and interferon-alpha2b in metastatic melanomaAnn Oncol200617457157716469753
   PubMed Web of Science ®Google Scholar
• AtkinsMBHsuJLeeSPhase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial coordinated by the Eastern Cooperative Oncology GroupJ Clin Oncol200826355748575419001327
   PubMed Web of Science ®Google Scholar
• IvesNJStoweRLLoriganPWheatleyKChemotherapy compared with biochemotherapy for the treatment of metastatic melanoma: a meta-analysis of 18 trials involving 2,621 patientsJ Clin Oncol200725345426543418048825
   PubMed Web of Science ®Google Scholar
• O’DaySJAtkinsMBBoasbergPPhase II multicenter trial of maintenance biotherapy after induction concurrent biochemotherapy for patients with metastatic melanomaJ Clin Oncol200927366207621219917850
   PubMed Web of Science ®Google Scholar
• SmalleyKSMHerlynMTargeting intracellular signaling pathways as a novel strategy in melanoma therapeuticsAnn N Y Acad Sci20051059162516382039
   PubMed Web of Science ®Google Scholar
• SpoffordLSAbelEVBoisvert-AdamoKAplinAECyclin D3 expression in melanoma cells is regulated by adhesion-dependent phosphatidylinositol 3-kinase signaling and contributes to G1-S progressionJ Biol Chem200628135256442565116815849
   PubMed Web of Science ®Google Scholar
• BeadlingCJacobson-DunlopEHodiFSKIT gene mutations and copy number in melanoma subtypesClin Cancer Res200814216821682818980976
   PubMed Web of Science ®Google Scholar
• WilhelmSMAdnaneLNewellPPreclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signalingMol Cancer Ther20087103129314018852116
   PubMed Web of Science ®Google Scholar
• FlahertyKPuzanovISosmanJPhase I study of PLX4032: Proof of concept for V600E BRAF mutation as a therapeutic target in human cancerJ Clin Oncol20092715s (Supplement; abstract 9000)).
   Google Scholar
• PuzanovINathansonKChapmanPPLX4032, a highly selective V600E BRAF kinase inhibitor: Clinical correlation of activity with pharmacokinetic and pharmacodynamic parameters in a phase I trialJ Clin Oncol (Meeting Abstracts)20092715s Suppl; abstr 9021.
   Google Scholar
• ClinicalTrials.govA Study of RO5185426 in previously treated patients with metastatic melanoma Available at: http://www.clinicaltrials.gov/ct2/show/NCT00949702?term=plx-4032&rank=2 [Accessed Dec 14, 2009].
   Google Scholar
• Clinical Trials.govA study of RO5185426 in comparison with dacarbazine in previously untreated patients with metastatic melanoma Available at: http://www.clinicaltrials.gov/ct2/show/NCT01006980?term=RO5185426&rank=3 [Accessed Dec 14, 2009].
   Google Scholar
• WymanKAtkinsMBPrietoVMulticenter Phase II trial of high-dose imatinib mesylate in metastatic melanoma: significant toxicity with no clinical efficacyCancer200610692005201116565971
   PubMed Web of Science ®Google Scholar
• CarvajalRChapmanPWolchokJA phase II study of imatinib mesylate (IM) for patients with advanced melanoma harboring somatic alterations of KITJ Clin Oncol (Meeting Abstracts)20092715s Suppl; abstr 9001.
   Google Scholar
• ZhuYSiLKongYResponse to sunitinib in Chinese KIT-mutated metastatic mucosal melanomaJ Clin Oncol (Meeting Abstracts)200927Suppl Suppl abstr e20017.
   Google Scholar
• WoodmanSTrentJStemke-HaleKSelective activity of dasatinib for the most common KIT mutation in melanoma (L576P)J Clin Oncol (Meeting Abstracts)20092715s Suppl; abstr 9019.
   Google Scholar
• Clinical TrialsA study of AMNN107 against dacarbazine (DTIC) in the treatment of metastatic and/or inoperable melanoma harboring a c-Kit mutation Available at: http://www.clinicaltrials.gov/ct2/show/NCT01028222?term=kit+melanoma&rank=1 [Accessed Dec 14, 2009].
   Google Scholar
• Clinical TrialsClinical trial of sutent to treat metastatic melanoma Available at: http://www.clinicaltrials.gov/ct2/show/NCT00631618?term=kit+melanoma&rank=2. Accessed Dec 14, 2009.
   Google Scholar
• Clinical TrialsImatinib mesylate in treating patients with stage III or stage IV melanoma that cannot be removed by surgery Available at: http://www.clinicaltrials.gov/ct2/show/NCT00470470?term=kit+melanoma&rank=3. Accessed Dec 14, 2009.
   Google Scholar
• Clinical TrialsImatinib in patients with mucosal or acral/lentiginous melanoma Available at: http://www.clinicaltrials.gov/ct2/show/NCT00424515?term=kit+melanoma&rank=4. Accessed Dec 14, 2009.
   Google Scholar
• Clinical TrialsTrial of imatinib (Gleevec®) in selected patients with metastatic melanoma Available at: http://www.clinicaltrials.gov/ct2/show/NCT00881049?term=kit+melanoma&rank=5. Accessed Dec 14, 2009.
   Google Scholar
• Clinical TrialsSU011248 in patients with metastatic mucosal or acral/lentiginous melanoma Available at: http://www.clinicaltrials.gov/ct2/show/NCT00577382?term=kit+melanoma&rank=6. Accessed Dec 14, 2009.
   Google Scholar
• FifeKMColmanMHStevensGNDeterminants of outcome in melanoma patients with cerebral metastasesJ Clin Oncol20042271293130015051777
   PubMed Web of Science ®Google Scholar
• MoriYKondziolkaDFlickingerJCStereotactic radiosurgery for cerebral metastatic melanoma: factors affecting local disease control and survivalInt J Radiat Oncol Biol Phys19984235815899806518
   PubMed Web of Science ®Google Scholar
• YuCChenJCTApuzzoMLJMetastatic melanoma to the brain: prognostic factors after gamma knife radiosurgeryInt J Radiat Oncol Biol Phys20025251277128711955740
   PubMed Web of Science ®Google Scholar
• SelekUChangELHassenbuschSJStereotactic radiosurgical treatment in 103 patients for 153 cerebral melanoma metastasesInt J Radiat Oncol Biol Phys20045941097110615234044
   PubMed Web of Science ®Google Scholar
• RadbillAEFiveashJFFalkenbergETInitial treatment of melanoma brain metastases using gamma knife radiosurgery: an evaluation of efficacy and toxicityCancer2004101482583315305416
   PubMed Web of Science ®Google Scholar
• StoneACooperJKoenigKLGolfinosJGOratzRA comparison of survival rates for treatment of melanoma metastatic to the brainCancer Invest200422449249715565805
   PubMed Web of Science ®Google Scholar